Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review)

ARSENE DAN SPINU1,2, OVIDIU GABRIEL BRATU1,3, CAMELIA CRISTINA DIACONU1,4, ANA MARIA ALEXANDRA STANESCU1, SIMONA BUNGA5, OVIDIU FRATILA6, ROXANA BOHILTEA1,7 and DAN LIVIU DOREL MISCHIANU1,3

11Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest; 2Urology Department, Emergency University Central Military Hospital, 010825 Bucharest; 3Academy of Romanian Scientists, 050045 Bucharest; 4Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 014461 Bucharest; 5Department of Pharmacy, University of Oradea, Faculty of Medicine and Pharmacy, 410028 Oradea; 6Department of Medical Disciplines, University of Oradea, Faculty of Medicine and Pharmacy, 410087 Oradea; 7Department of Obstetrics and Gynecology, University Emergency Hospital, 050098 Bucharest, Romania

Received February 3, 2020; Accepted March 3, 2020

DOI: 10.3892/etm.2020.8664

Abstract. Botulinum toxin is a substance produced by Clostridium Botulinum and is responsible for human botulism. This substance is a poison, a neurotoxin, but used in limited quantities it can be a cure for some diseases. It is well connected to a large variety of medical applications. The mechanism of action relies on blocking the acetylcholine at the neuromuscular junction, which blocks the transmission of the nervous impulse with secondary flaccid paralysis. In urology, its role in idiopathic overactive bladder and neurogenic bladder is well known. We performed a thorough review using PubMed and other databases, revising the mechanisms of botulinum toxin action in urologic pathology, treatment procedures and other options. Botulinum toxin is a well-studied substance with a large number of applications in medicine. In urologic pathology, overactive bladder and neurogenic bladder are backed by robust studies that support the therapeutic role of this substance. The toxin has multiple effects, such as inhibition of the nerve growth factor, blocking the bladder sensory afferent pathway and apoptotic effect on the prostate tissue, by inhibiting the substance P, altering the nociceptive pathways. Interstitial cystitis and other rare pathologies show promising results, but further studies are needed. The role of botulinum toxin in benign prostatic hyperplasia is still not elucidated.

Contents

1. Introduction
2. Materials and methods
3. Results
4. The mechanism of action
5. Studies of efficiency
6. Conclusions

1. Introduction

The first medical use of botulinum toxin dates back to 1988, when Dykstra et al used it in detrusor external sphincter dyssynergia (1). Since then, this poison began to be widely used in medical practice for chronic migraines, chronic pain, head and neck dystonias, strabismus, hyperhidrosis and anal fissures (2). Botulinum toxin is a poison, a neurotoxin, but used in limited quantities it can be a cure for some diseases. The first medical use of this neurotoxin dates back to 1981, when Scott used it to correct strabismus (3). American Urological Association (AUA) recommends this type of treatment for refractory overactive bladder. Federal Drug Administration (FDA) officially approved the usage of botulinum toxin in August 2011.

As of general recommendations, botulinum toxin is the third line of treatment option for overactive bladder. Although it has clear benefits, there are also side effects that can not be ignored including urinary tract infections and elevated post-void residual volume.

There are eight different strains of toxin: A, B, C1, C2, D, E, F and G. The most widely used in medicine is the A subtype. This strain has much longer lasting effects than all the others, which is a great advantage given the fact that the instillation is an invasive procedure. The B subtype is also used, but it has a shorter duration of action and there are not many studies on it.

Correspondence to: Professor Ovidiu Gabriel Bratu, ‘Carol Davila’ University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
E-mail: ovi78doc@yahoo.com

Key words: botulinum toxin, overactive bladder, neurologic bladder, treatment, analysis
2. Materials and methods

PubMed and Scopus databases were searched for reviews and original articles regarding Botulinum toxin overactive bladder and neurogenic bladder. Morphopathology and the clinical use were envisaged. Side effects were taken to consideration.

3. Results

Botulinum toxin has many medical uses. Its effect on overactive bladder and neurogenic bladder were searched. These two pathologies have many common characteristics, but also some differences. Overactive bladder, so-called idiopathic bladder, reunites all the causes that cannot be included in the neurogenic bladder category, so it is an exclusion diagnosis. Overactive bladder (OAB) is defined by the International Continence Society as urgency with or without urinary incontinence (UI), usually associated with frequency and nocturia. It is a multifactorial and common disease, associated with detrimental effects on the quality of life and a great economic burden. Neurogenic detrusor overactivity (NDO) is defined as a special type of OAB, when there is a relevant underlying neurological condition, such as spinal cord injury or multiple sclerosis (4-6).

4. The mechanism of action

Botulinum toxin is one of the most potent neurotoxins. It has been calculated that 1 g of this purified substance can kill over 1 million people (7). It is a 150 kDa polypeptide with three separate domains: N, middle and C. The C domain binds to the pre-synaptic membrane, the N domain is a specific polypeptidase and the middle domain facilitates the L chain into the cytosol. The most remarkable aspect is the affinity of this substance for the most active synapses.

The mechanism of action relies on blocking the acetylcholine at the neuromuscular junction, which blocks the transmission of the nervous impulse with secondary flaccid paralysis.

The toxin has multiple effects such as inhibition of the nerve growth factor, it blocks the bladder sensory afferent pathway, it has apoptotic effect on the prostate tissue, by inhibiting the substance P, altering nociceptive pathways (8-10). This type of paralysis lasts from 3 to 6 months when injected into the neuromuscular junction of the skeletal muscle and more than one year if the injection is made into the smooth muscle.

There are many commercially available products, starting with Botox (onabotulinotoxin), Dysport (abobotulinotoxin) and Xeomin (incobotulinotoxin). There is no direct equivalency between doses, but it is generally accepted that one unit of onabotulinotoxin is equivalent to 3-5 units of abobotulinotoxin. There is still no equivalency with incobotulinotoxin (11-13).

Its usage is accepted for overactive bladder, in fact both European and American guidelines recommend this type of treatment as a third line therapy. There are numerous studies that compare the effectiveness of botulinum toxin against oral therapies.

5. Studies of efficiency

One of the most comprehensive meta-analysis was carried out by Drake et al (14). In the study, 56 randomized controlled trials were revised comparing onabotulinotoxin to oral medication, including mirabegron and anticholinergics. They used network meta-analysis and network meta regression for comparison and adjusted the baseline for severity symptoms. The set period was 12 weeks, the span of the review ranged from 2007 to 2014 and only studies in English were eligible. All medications had higher efficiency than placebo, with onabotulinotoxin being superior to oral medication in every aspect of micturition, urgency, urinary incontinence episodes. Regarding side effects, onabotulinotoxin led to urinary tract infection, urinary retention, bacteriuria, increased residual urine volume and haematuria. Onabotulinotoxin had also the best results in relieving the overactive bladder symptoms.

One suggestive example of the superiority of this toxin over oral medication was presented by Ferreira et al (15). Their small study included 61 patients who were randomly selected to oral or toxin medication. Of the patients 23.5% with oral medication and 11.8% from the onabotulinotoxin group were non-responders. Macroscopic haematuria was present in 28% of the onabotulinotoxin patients and dry mouth in 72% of the patients with oral medication. The study reported the superiority of onabotulinotoxin to oral medication in almost all aspects of urodynamics, continence and quality of life. Most important, all patients were from the neurogenic bladder group, not from the overactive bladder group. Schurch et al (16) also reported an improvement in quality of life. Karsenty et al (17) reported urinary continence in 40-80% of the cases.

There are other studies that compared the toxin to placebo. One of the most recent reviews is by Zhou et al (18). Using many databases, they searched for the efficacy and safety of botulinum toxin in the treatment of neurogenic bladder. They identified four articles including 932 patients, from whom 450 were included in the botulinotoxin group and 482 in the control group. The authors found that onabotulinotoxin is very efficient in comparison to placebo, regardless of the dosage. Also, treatment complications are mostly related to urinary tract and include urinary infection, urinary retention, and haematuria (19).

One of the most important issues of overactive and neurologic bladder is the high pressure inside the bladder during voiding. There are many discussions regarding the need of urodynamics in patients following treatment for overactive or neurologic bladder. Koschorke et al (20) evaluated the need for urodynamics in patients with neurologic overactive bladder under treatment with onabotulinotoxin. Their study group included 148 patients who were evaluated before and 6 weeks after receiving the treatment. High intravesical pressure leads to renal failure later, so it is mandatory to evaluate the patient carefully. The authors determined a pressure higher than 40 mmH2O before receiving the treatment indicates a poor prognosis for urodynamic outcomes. Even if 66% of the patients became continent, one out of five had high intravesical pressure, putting the upper urinary tract at risk. After repeating the treatment, 10 out of 18 patients achieved normal vesical pressure. There were still 8 patients out of 148 who did not achieve a normal intravesical pressure status. Thus, these authors underlined the need for urodynamics (20).

Another debated problem was the dosage of the substance. Every pharmaceutical company that produces some form of the toxin has its own measure, there is no a standardized one. Moreover, there is still debate on what quantity of the same
toxin has greater efficiency. Zhang et al (21), tried to elucidate this subject. Participants (1,879) from eight studies were included in their analysis. Besides the good efficiency of the drug, the authors emphasize the differences that appear with varying doses. Their comparison between 200 and 300 units did not find any significant differences, but the Cochrane review has some interesting findings: lower doses of the drug appear to have beneficial effects, but higher doses have better efficiency (and also a higher rate of side effects), suburothelial injection seems to have the same effect as intradetrusor injection, and the effect is dose and toxin type-dependent (22).

Many authors considered that single dose treatment is the optimal medical approach, but there are studies that have found that repeat treatment can be used in the same patient. Denys et al (23) proved that patients with neurogenic bladder can be treated with repeated injections of botulinum toxin. Moreover, even patients who do not achieve a good performance status after the first dose can respond better after repeated treatment. Other studies also concluded that there is no refractory response with repeated treatment.

The first study that investigated this toxin in the treatment of neurogenic bladder dates back to 2005. Schurch et al (24) evaluated 59 patients with neurogenic bladder who received a single dose of toxin (200 or 300 units) or placebo. The results were spectacular, a significant improvement in all aspects was observed.

Another aspect is the place of injection. As yet, there is no standardized recommendation for injection site. There are studies that compared trigone versus outside the trigone and concluded that trigonal injection is superior (25,26).

The side effects of this substance in pregnancy are less studied. FDA put botulinum toxin in category C for pregnant women, indicating a major teratogen. Moreover, great care must be taken in elderly patients or those aged under 18 years.

The follow up is another debated problem. There are no guidelines regarding the follow-up of these patients, but given the fact that these diseases are progressive, the patients should be monitored.

There are studies that tried to link this medication to other neurological disorders such as Parkinson's disease, multiple sclerosis, spinal cord injury, cerebrovascular accident and myelomeningocele. Some of the results were promising, but there are no standardized recommendations.

Cheng et al (27), in their review, evaluated the efficacy and safety of the toxin in the treatment of neurogenic bladder. In the same study, they evaluated the differences regarding the dosage. They found out that there are no differences between 200 and 300 units. Patients (1,915) from six studies were included in their review, with great improvements in the toxin type of neurogenic bladder. In the same study, they evaluated the differences regarding the dosage and concluded that it is safe, but caution should be taken. Post voiding residue is a very important complication that needs to be monitored and also the success of this procedure is relatively lower in frail patients.

6. Conclusions

Evidence for the use of botulinum toxin in overactive bladder and neurogenic bladder continues to accumulate. This type of treatment offers a reasonable alternative to neural stimulation. It has limited side effects, generally related to the surgical procedure.

One severe possible complication is the post voiding residue. The elderly and neurological patient should be treated carefully. Another complication is the high intravesical pressure, which may lead in time to renal failure. Urodynamics in this type of patients is mandatory, pre- and post-injecting the medication. Patients with multiple sclerosis have increased risk of urinary infections, so particular attention is recommended.

Novel applications of botulinum toxin may be benign prostatic hyperplasia, interstitial cystitis, and chronic pelvic pain, but there are no standardised approaches. There is still no consensus regarding the injection pattern or a regular dose. Repeated treatment seems to offer good results in selected cases. One possible application of this treatment could be for patients who have undergone augmentation cystoplasty for the same disease. Also, there is no standardised follow-up for this type of patients, and no guidelines. There are still many questions and many fields in which botulinum toxin can be used. For some diseases, such as overactive bladder and neurologic bladder, the indications are clear, and these indications may be expanded to other urologic diseases in the future.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

AMAS, SB, OF and RB collected, analyzed and interpreted the patient data regarding the metabolic and cardiovascular benefits of GLP-1 agonists. ADS, DLDM, OGB and CCD substantially contributed to the conception of the work and interpretation of data; also, they drafted the manuscript and were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.
References

1. Dykstra DD, Sidi AA, Scott AB, Pagel JM and Goldish GD: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139: 919-922, 1988.
2. Montecucco C and Malogò J: Botulinum neurotoxins: Revival of an old killer. Curr Opin Pharmacol 5: 274-279, 2005.
3. Scott AB: Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79: 734-740, 1981.
4. Abrams P, Cardozo L, Fall M, Grifffiths D, Rosier P, Ulmsten U, van Kerrebrouck P, Victor A and Wein A: Standardisation Sub-committee of the International Continence Society: The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178, 2002.
5. Ainsworth DE, Milsom J, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kellerhe C, Hampel C, Artibani W, et al: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 50: 1306-1315, 2006.
6. Sacco E, Tenfori D, A’daddessi A, Pinto F, Racioppiti M, Totoro A, D’Agostino D, Marangi F and Bassi P: Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol 2: 11-24, 2010.
7. Harper M, Fowler CJ and Dasgupta P: Botulinum toxin and its applications in the lower urinary tract. BJU Int 93: 702-706, 2004.
8. Ha JS, Park E and Kim JC: Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity. Urology 78: e721.e1-e721.e6, 2011.
9. Frenkl TL and Rackley RR: Injectable neuromodulatory agents: Botulinum toxin therapy. Urol Clin North Am 32: 89-99, 2005.
10. Ikeda Y, Zabbarova IV, Birder EA, de Groot WC, McCarthy CJ, Hanna-Mitchell AT and Kanaan AJ: Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol 62: 1157-1164, 2012.
11. Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhaes M, Correia AP, Bastos-Lima A, Martins R and Castro-Caldas A: DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 12: 1013-1018, 1997.
12. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, et al: A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64: 6-12, 1998.
13. Ranoux D, Gury C, Fondalar J, Mas JL and Zuber M: Respective potencies of Botox and Dysport: A double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72: 459-462, 2002.
14. Drake MJ, Nitti W, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Galvanil JM, Fleetwood K, James D and Chapple CR: Comparative assessment of the efficacy of onabotulinum toxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: A systematic review and network meta-analysis. BJU Int 120: 61-66, 2017.
15. Ferreira RS, D’Antomenica CA, Oelke M and Carneiro MR: Intradetrusor onabotulinum toxin A injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: Results of a randomized, controlled, 24-week trial. Einstein (Sao Paulo) 16: eAO4207, 2018.
16. Schuchard B, Denys P, Kozima CM, Reese PR, Slaton T and Barron RL: Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52: 850-858, 2007.
17. Karsenty G, Denys P, Amarengo G, De Seze M, Gamé X, Haaf F, Kerdraon J, Perrouin-Verbe B, Ruffion A, Saussine C, et al: Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/bladder overactivity: A systematic literature review. Eur Urol 53: 275-287, 2008.
18. Zhou X, Yan HL, Cui YS, Zong HT and Zhang Y: Efficacy and safety of onabotulinum toxin A in treating neurogenic detrusor overactivity: A systematic review and meta-analysis. Chin Med J (Engl) 128: 963-968, 2015.
19. Bumbu A, Pasca B, Tit DM, Bungau S and Bumbu G: The effects of soy isoflavones and hormonal replacing therapy on the incidence and evolution of postmenopausal female urinary incontinence. Farmacia 64: 419-422, 2016.
20. Koschorke M, Leitner L, Sadri H, Knüper SC, Mehnert U and Kessler TM: Intradetrusor onabotulinum toxin A injections for refractory neurogenic detrusor overactivity incontinence: Do we need urodynamic investigation for outcome assessment? BJU Int 120: 848-854, 2017.
21. Zhang R, Xu Y, Yang S, Liang H, Zhang Y and Liu Y: Onabotulinum toxin A for neurogenic detrusor overactivity and dose differences: A systematic review. Int Braz J Urol 41: 207-219, 2015.
22. Duthie JB, Vincent M, Herbsron GP, Wilson DI and Wilson D: Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev: Dec 7, 2011 (Epub ahead of print). doi: 10.1002/14651858.CD005493.pub3.
23. Denys P, Dmochnowski R, Aliotta P, Castro-Diaz D, Blok B, Ehtans K, Aboulshwareb T, Magyar A and Kennedy M: Positive outcomes with first onabotulinum toxin A treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity. BJU Int 119: 926-932, 2017.
24. Schuchard B, de Sèze M, Denys P, Chartier-Kastler E, Haaf B, Everaert K, Plante P, Perrouin-Verbe B, Kamar C, Fraczek S, et al: Botulinum neurotoxin serotypes A and B effectiveness and safety of Botulinum neurotoxin serotypes A and B in patients with neurogenic detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. PLoS One 11: e0159307, 2016.
25. Trinh H, Irishi V, Diaz M and Atieno H: Outcomes of intradetrusor onabotulinum toxin A therapy in overactive bladder refractory to sacral neuromodulation. Int Neurourol J 23: 226-233, 2019.
26. Spina D, Brout O, Marcu D, Misichiana D, Huica R, Surcel M, Munteanu A, Socca B, Bodean O and Ursaciuc C: The use of ELISA and PCR in identifying correlations between viral infections and benign prostate hypertrophy. Rev Chim Buchar 69: 645-649, 2018.
27. Spina D, Rüdulescu A, Brout O, Checheriti IA, Ranetti AE and Misichiana D: Giant condyloma acuminatum - Buschke-Lowenstein disease - a literature review. Chirurgia (Bucur) 109: 445-454, 2014.
28. Jiang JF and Kuo HC: Novel applications of onabotulinum toxin A in lower urinary tract dysfunction. Toxins (Basel) 10: 260, 2018.
29. Manea M, Marcu D, Pantea Stoian A, Gaman MA, Gaman AM, Socca B, Neagu TP, Stanescu AMA, Brout OG and Diaconu CC: Heart failure with preserved ejection fraction and atrial fibrillation: A review. Rev Chim Buchar 69: 4180-4184, 2018.
30. Draghici T, Negreanu L, Brout OG, Tincu R, Socca B, Iancu MA, Stanescu AM and Diaconu C: Liver abnormalities in patients with heart failure. Arch Balk Med Union 53: 76-81, 2018.
31. Liao CH, Wang CC and Jiang YH: Intravesical onabotulinum toxin A injection for overactive bladder patients with frailty, medical comorbidities or prior lower urinary tract surgery. Toxins (Basel) 8: 91, 2016.